|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
11
|
|
pubmed:dateCreated |
2007-10-15
|
|
pubmed:abstractText |
Endothelin receptor antagonism has become an important component in the treatment of pulmonary arterial hypertension (PAH) associated with connective tissue disease (CTD). The purpose of this study was to analyse the safety and effectiveness of sitaxsentan, a selective antagonist of the ET(A) receptor, in a cohort of patients with PAH and CTD. Short-term clinical and haemodynamic effects and longer-term follow-up data are presented.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0003-4967
|
|
pubmed:author |
pubmed-author:BarstRobyn JRJ,
pubmed-author:FrostAdaani EAE,
pubmed-author:GirgisReda ERE,
pubmed-author:HillNicholas SNS,
pubmed-author:HornEvelyn MEM,
pubmed-author:LanglebenDavidD,
pubmed-author:McLaughlinVallerie VVV,
pubmed-author:OudizRonald JRJ,
pubmed-author:RobbinsIvan MIM,
pubmed-author:SeiboldJames RJR,
pubmed-author:ShapiroShelleyS,
pubmed-author:TapsonVictor FVF
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
66
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1467-72
|
|
pubmed:dateRevised |
2010-11-2
|
|
pubmed:meshHeading |
pubmed-meshheading:17472992-Adolescent,
pubmed-meshheading:17472992-Adult,
pubmed-meshheading:17472992-Aged,
pubmed-meshheading:17472992-Antihypertensive Agents,
pubmed-meshheading:17472992-Blood Pressure,
pubmed-meshheading:17472992-Cardiac Output,
pubmed-meshheading:17472992-Connective Tissue Diseases,
pubmed-meshheading:17472992-Dose-Response Relationship, Drug,
pubmed-meshheading:17472992-Double-Blind Method,
pubmed-meshheading:17472992-Female,
pubmed-meshheading:17472992-Follow-Up Studies,
pubmed-meshheading:17472992-Humans,
pubmed-meshheading:17472992-Hypertension, Pulmonary,
pubmed-meshheading:17472992-Isoxazoles,
pubmed-meshheading:17472992-Male,
pubmed-meshheading:17472992-Middle Aged,
pubmed-meshheading:17472992-Quality of Life,
pubmed-meshheading:17472992-Receptor, Endothelin A,
pubmed-meshheading:17472992-Thiophenes,
pubmed-meshheading:17472992-Treatment Outcome,
pubmed-meshheading:17472992-Vascular Resistance,
pubmed-meshheading:17472992-Walking
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Selective endothelin A receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease.
|
|
pubmed:affiliation |
Johns Hopkins University, School of Medicine, Baltimore, Maryland, USA.
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
